WO2023214212 - COMPOSITIONS AND USES OF CD38 AND ICAM1 ANTIBODIES
National phase entry is expected:
Publication Number
WO/2023/214212
Publication Date
09.11.2023
International Application No.
PCT/IB2023/000244
International Filing Date
05.05.2023
Title **
[English]
COMPOSITIONS AND USES OF CD38 AND ICAM1 ANTIBODIES
[French]
COMPOSITIONS ET UTILISATIONS D'ANTICORPS ANTI-CD38 ET ANTI-ICAM1
Applicants **
VIRTUOSO BINCO, INC.
Inventors
CHEN, Xiaocheng
Priority Data
PCT/IB2022/000324
06.05.2022
IB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5076 | |
| EPO | Filing, Examination, Granting | 108930 | |
| Japan | Filing, Examination, Granting | 4847 | |
| South Korea | Filing, Examination, Granting | 8526 | |
| USA | Filing, Examination, Granting | 22710 |
Total:
150,089
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are recombinant CD38 and ICAM1 antibody compositions and uses of these compositions in treating cancer.[French]
L'invention concerne des compositions d'anticorps anti-CD38 et anti-ICAM1 recombinantes et des utilisations de ces compositions dans le traitement du cancer.